Inclisiran - new hope in the management of lipid disorders?

Drugs reducing plasma concentrations of apolipoprotein-B (ApoB) containing lipoproteins have been demonstrated to reduce the risk of cardiovascular disease (CVD) in both primary and secondary prevention. Despite the demonstrated efficacy of statins and ezetimibe on low-density lipoprotein (LDL) concentration and long-term CVD risk, a large number of patients do not achieve their therapeutic goals. The introduction of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) protein was a milestone in the treatment of lipid disorders, as their administration leads to unprecedentedly low LDL-C concentrations.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Review Article Source Type: research